NCT02705547View on ClinicalTrials.gov

Rosuvastatin (Crestor) in Friedreich Ataxia

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

May 31, 2016

Primary Completion Date

August 4, 2017

Study Completion Date

August 4, 2017

Conditions
Friedreich Ataxia
Interventions
DRUG

Rosuvastatin

Daily oral administration of Rosuvastatin (10 mg) for 3 months

Trial Locations (1)

19103

Children's Hospital of Philadelphia, Philadelphia

All Listed Sponsors
collaborator

Friedreich's Ataxia Research Alliance

OTHER

lead

Children's Hospital of Philadelphia

OTHER

NCT02705547 - Rosuvastatin (Crestor) in Friedreich Ataxia | Biotech Hunter | Biotech Hunter